{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:12:42Z","timestamp":1789974762216,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001409"],"award-info":[{"award-number":["UL1TR001409"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA051008"],"award-info":[{"award-number":["P30-CA051008"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA135069"],"award-info":[{"award-number":["R01CA135069"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with type 1 diabetes (T1DM) typically have normal or even elevated plasma high density lipoprotein (HDL) cholesterol concentrations; however, HDL protein composition can be altered without a change in cholesterol content. Alteration of the HDL proteome can result in dysfunctional HDL particles with reduced ability to protect against cardiovascular disease (CVD). The objective of this study was to compare the HDL proteomes of youth with T1DM and healthy controls (HC) and to evaluate the influence of glycemic control on HDL protein composition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a cross-sectional case\u2013control study. Blood samples were obtained from patients with T1DM and HC. HDL was isolated from plasma by size-exclusion chromatography and further purified using a lipid binding resin. The HDL proteome was analyzed by mass spectrometry using label-free SWATH peptide quantification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Samples from 26 patients with T1DM and 13 HC were analyzed and 78 HDL-bound proteins were measured. Youth with T1DM had significantly increased amounts of complement factor H related protein 2 (FHR2; adjusted P\u2009&lt;\u20090.05), compared to HC. When patients were analyzed based on glucose control, several trends emerged. Some proteins were altered in T1DM and not influenced by glycemic control (e.g. FHR2) while others were partially or completely corrected with optimal glucose control (e.g. alpha-1-beta glycoprotein, A1BG). In a subgroup of poorly controlled T1DM patients, inter alpha trypsin inhibitor 4 (ITIH4) was dramatically elevated (P\u2009&lt;\u20090.0001) and this was partially reversed in patients with optimal glucose control. Some proteins including complement component C3 (CO3) and albumin (ALB) were significantly different only in T1DM patients with optimal glucose control, suggesting a possible effect of exogenous insulin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Youth with T1DM have proteomic alterations of their HDL compared to HC, despite similar concentration of HDL cholesterol. The influence of these compositional changes on HDL function are not yet known. Future efforts should focus on investigating the role of these HDL associated proteins in regard to HDL function and their role in CVD risk in patients with T1DM.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>NCT02275091<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12933-019-0846-9","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T07:02:56Z","timestamp":1553756576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Proteomic alterations of HDL in youth with type 1 diabetes and their associations with glycemic control: a case\u2013control study"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct02275091","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-7955","authenticated-orcid":false,"given":"Evgenia","family":"Gourgari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Playford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslav","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"issue":"17","key":"846_CR1","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1161\/CIR.0000000000000094","volume":"130","author":"DM Maahs","year":"2014","unstructured":"Maahs DM, Daniels SR, de Ferranti SD, Dichek HL, Flynn J, Goldstein BI, Kelly AS, Nadeau KJ, Martyn-Nemeth P, Osganian SK, et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014;130(17):1532\u201358.","journal-title":"Circulation"},{"issue":"8","key":"846_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.0686","volume":"317","author":"D Dabelea","year":"2017","unstructured":"Dabelea D, Stafford JM, Mayer-Davis EJ, D\u2019Agostino R Jr, Dolan L, Imperatore G, Linder B, Lawrence JM, Marcovina SM, Mottl AK, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA. 2017;317(8):825\u201335.","journal-title":"JAMA"},{"issue":"12","key":"846_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11892-017-0968-y","volume":"17","author":"E Gourgari","year":"2017","unstructured":"Gourgari E, Dabelea D, Rother K. Modifiable risk factors for cardiovascular disease in children with type 1 diabetes: can early intervention prevent future cardiovascular events? Curr Diabetes Rep. 2017;17(12):134.","journal-title":"Curr Diabetes Rep"},{"issue":"4","key":"846_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jpeds.2005.04.068","volume":"147","author":"DM Maahs","year":"2005","unstructured":"Maahs DM, Maniatis AK, Nadeau K, Wadwa RP, McFann K, Klingensmith GJ. Total cholesterol and high-density lipoprotein levels in pediatric subjects with type 1 diabetes mellitus. J Pediatr. 2005;147(4):544\u20136.","journal-title":"J Pediatr"},{"issue":"3","key":"846_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc08-1775","volume":"32","author":"J Guy","year":"2009","unstructured":"Guy J, Ogden L, Wadwa RP, Hamman RF, Mayer-Davis EJ, Liese AD, D\u2019Agostino R Jr, Marcovina S, Dabelea D. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for diabetes in youth case\u2013control study. Diabetes Care. 2009;32(3):416\u201320.","journal-title":"Diabetes Care"},{"issue":"11","key":"846_CR6","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s00125-007-0808-8","volume":"50","author":"L Persegol","year":"2007","unstructured":"Persegol L, Foissac M, Lagrost L, Athias A, Gambert P, Verges B, Duvillard L. HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 2007;50(11):2384\u20137.","journal-title":"Diabetologia"},{"issue":"10","key":"846_CR7","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.2337\/dc07-0030","volume":"30","author":"PH Groop","year":"2007","unstructured":"Groop PH, Thomas MC, Rosengard-Barlund M, Mills V, Ronnback M, Thomas S, Forsblom C, Taskinen MR, Viberti G. HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes. Diabetes Care. 2007;30(10):2706\u20137.","journal-title":"Diabetes Care"},{"issue":"1","key":"846_CR8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12933-018-0802-0","volume":"17","author":"E Gourgari","year":"2018","unstructured":"Gourgari E, Playford MP, Campia U, Dey AK, Cogen F, Gubb-Weiser S, Mete M, Desale S, Sampson M, Taylor A, et al. Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study. Cardiovasc Diabetol. 2018;17(1):158.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"846_CR9","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1021\/pr5011586","volume":"14","author":"J Marsillach","year":"2015","unstructured":"Marsillach J, Becker JO, Vaisar T, Hahn BH, Brunzell JD, Furlong CE, de Boer IH, McMahon MA, Hoofnagle AN, Group DER. Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis. J Proteome Res. 2015;14(5):2046\u201354.","journal-title":"J Proteome Res"},{"key":"846_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.plipres.2014.07.003","volume":"56","author":"R Birner-Gruenberger","year":"2014","unstructured":"Birner-Gruenberger R, Schittmayer M, Holzer M, Marsche G. Understanding high-density lipoprotein function in disease: recent advances in proteomics unravel the complexity of its composition and biology. Prog Lipid Res. 2014;56:36\u201346.","journal-title":"Prog Lipid Res"},{"issue":"2","key":"846_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2215\/CJN.06560714","volume":"10","author":"C Kopecky","year":"2015","unstructured":"Kopecky C, Genser B, Drechsler C, Krane V, Kaltenecker CC, Hengstschlager M, Marz W, Wanner C, Saemann MD, Weichhart T. Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis. Clin J Am Soc Nephrol. 2015;10(2):224\u201331.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"846_CR12","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.2337\/db12-1753","volume":"62","author":"SM Gordon","year":"2013","unstructured":"Gordon SM, Davidson WS, Urbina EM, Dolan LM, Heink A, Zang H, Lu LJ, Shah AS. The effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youth. Diabetes. 2013;62(8):2958\u201367.","journal-title":"Diabetes"},{"issue":"11","key":"846_CR13","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1210\/jc.2015-2566","volume":"100","author":"E Gourgari","year":"2015","unstructured":"Gourgari E, Lodish M, Shamburek R, Keil M, Wesley R, Walter M, Sampson M, Bernstein S, Khurana D, Lyssikatos C, et al. Lipoprotein particles in adolescents and young women with PCOS provide insights into their cardiovascular risk. J Clin Endocrinol Metab. 2015;100(11):4291\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"846_CR14","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.1021\/pr100520x","volume":"9","author":"SM Gordon","year":"2010","unstructured":"Gordon SM, Deng J, Lu LJ, Davidson WS. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res. 2010;9(10):5239\u201349.","journal-title":"J Proteome Res"},{"issue":"12","key":"846_CR15","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1074\/mcp.M115.054031","volume":"14","author":"SM Gordon","year":"2015","unstructured":"Gordon SM, McKenzie B, Kemeh G, Sampson M, Perl S, Young NS, Fessler MB, Remaley AT. Rosuvastatin alters the proteome of high density lipoproteins: generation of alpha-1-antitrypsin enriched particles with anti-inflammatory properties. Mol Cell Proteom. 2015;14(12):3247\u201357.","journal-title":"Mol Cell Proteom"},{"issue":"9","key":"846_CR16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1074\/mcp.T600050-MCP200","volume":"6","author":"IV Shilov","year":"2007","unstructured":"Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, Keating SP, Hunter CL, Nuwaysir LM, Schaeffer DA. The Paragon algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteom. 2007;6(9):1638\u201355.","journal-title":"Mol Cell Proteom"},{"issue":"9","key":"846_CR17","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1021\/pr070492f","volume":"7","author":"WH Tang","year":"2008","unstructured":"Tang WH, Shilov IV, Seymour SL. Nonlinear fitting method for determining local false discovery rates from decoy database searches. J Proteome Res. 2008;7(9):3661\u20137.","journal-title":"J Proteome Res"},{"issue":"1","key":"846_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2012.06.068","volume":"224","author":"NN Mehta","year":"2012","unstructured":"Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, Raper A, Wilcox M, Baer A, DerOhannesian S, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224(1):218\u201321.","journal-title":"Atherosclerosis"},{"issue":"25","key":"846_CR19","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383\u201393.","journal-title":"N Engl J Med"},{"issue":"2","key":"846_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"846_CR21","doi-asserted-by":"publisher","first-page":"M110-004374","DOI":"10.1074\/mcp.M110.004374","volume":"10","author":"AP Diz","year":"2011","unstructured":"Diz AP, Carvajal-Rodriguez A, Skibinski DO. Multiple hypothesis testing in proteomics: a strategy for experimental work. Mol Cell Proteom. 2011;10(3):M110-004374.","journal-title":"Mol Cell Proteom"},{"issue":"Database issue","key":"846_CR22","first-page":"D377","volume":"41","author":"H Mi","year":"2013","unstructured":"Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 2013;41(Database issue):D377\u201386.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"846_CR23","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nprot.2013.092","volume":"8","author":"H Mi","year":"2013","unstructured":"Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 2013;8(8):1551\u201366.","journal-title":"Nat Protoc"},{"key":"846_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.atherosclerosis.2016.11.015","volume":"259","author":"SM Gordon","year":"2017","unstructured":"Gordon SM, Remaley AT. High density lipoproteins are modulators of protease activity: implications in inflammation, complement activation, and atherothrombosis. Atherosclerosis. 2017;259:104\u201313.","journal-title":"Atherosclerosis"},{"issue":"4","key":"846_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00125-012-2462-z","volume":"55","author":"E Hertle","year":"2012","unstructured":"Hertle E, van Greevenbroek MM, Stehouwer CD. Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia. 2012;55(4):881\u20134.","journal-title":"Diabetologia"},{"issue":"2","key":"846_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.atherosclerosis.2015.05.038","volume":"241","author":"A Hovland","year":"2015","unstructured":"Hovland A, Jonasson L, Garred P, Yndestad A, Aukrust P, Lappegard KT, Espevik T, Mollnes TE. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis. 2015;241(2):480\u201394.","journal-title":"Atherosclerosis"},{"issue":"4","key":"846_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molimm.2004.02.005","volume":"41","author":"SR de Cordoba","year":"2004","unstructured":"de Cordoba SR, Esparza-Gordillo J, de Jorge EG, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol. 2004;41(4):355\u201367.","journal-title":"Mol Immunol"},{"issue":"48","key":"846_CR28","doi-asserted-by":"publisher","first-page":"28977","DOI":"10.1074\/jbc.M115.669226","volume":"290","author":"K Haapasalo","year":"2015","unstructured":"Haapasalo K, van Kessel K, Nissila E, Metso J, Johansson T, Miettinen S, Varjosalo M, Kirveskari J, Kuusela P, Chroni A, et al. Complement factor H binds to human serum apolipoprotein e and mediates complement regulation on high density lipoprotein particles. J Biol Chem. 2015;290(48):28977\u201387.","journal-title":"J Biol Chem"},{"issue":"8","key":"846_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.it.2008.04.008","volume":"29","author":"M Jozsi","year":"2008","unstructured":"Jozsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol. 2008;29(8):380\u20137.","journal-title":"Trends Immunol"},{"key":"846_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1471-2407-8-241","volume":"8","author":"M Tian","year":"2008","unstructured":"Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 2008;8:241.","journal-title":"BMC Cancer"},{"issue":"6","key":"846_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00592-012-0407-0","volume":"49","author":"A Soggiu","year":"2012","unstructured":"Soggiu A, Piras C, Bonizzi L, Hussein HA, Pisanu S, Roncada P. A discovery-phase urine proteomics investigation in type 1 diabetes. Acta Diabetol. 2012;49(6):453\u201364.","journal-title":"Acta Diabetol"},{"issue":"1","key":"846_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.111.00823","volume":"62","author":"CW McDonough","year":"2013","unstructured":"McDonough CW, Gong Y, Padmanabhan S, Burkley B, Langaee TY, Melander O, Pepine CJ, Dominiczak AF, Cooper-Dehoff RM, Johnson JA. Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes. Hypertension. 2013;62(1):48\u201354.","journal-title":"Hypertension"},{"issue":"13\u201314","key":"846_CR33","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.clinbiochem.2014.05.002","volume":"47","author":"CK Noh","year":"2014","unstructured":"Noh CK, Kim SS, Kim DK, Lee HY, Cho HJ, Yoon SY, Lee GH, Hyun SA, Kim YJ, Kim HJ, et al. Inter-alpha-trypsin inhibitor heavy chain H4 as a diagnostic and prognostic indicator in patients with hepatitis B virus-associated hepatocellular carcinoma. Clin Biochem. 2014;47(13\u201314):1257\u201361.","journal-title":"Clin Biochem"},{"key":"846_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1477-5956-8-58","volume":"8","author":"SS Abdullah-Soheimi","year":"2010","unstructured":"Abdullah-Soheimi SS, Lim BK, Hashim OH, Shuib AS. Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci. 2010;8:58.","journal-title":"Proteome Sci"},{"issue":"11","key":"846_CR35","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1177\/1535370216629007","volume":"241","author":"G Fu","year":"2016","unstructured":"Fu G, Du Y, Chu L, Zhang M. Discovery and verification of urinary peptides in type 2 diabetes mellitus with kidney injury. Exp Biol Med. 2016;241(11):1186\u201394.","journal-title":"Exp Biol Med"},{"issue":"11","key":"846_CR36","doi-asserted-by":"publisher","first-page":"e112835","DOI":"10.1371\/journal.pone.0112835","volume":"9","author":"MA Sleddering","year":"2014","unstructured":"Sleddering MA, Markvoort AJ, Dharuri HK, Jeyakar S, Snel M, Juhasz P, Lynch M, Hines W, Li X, Jazet IM, et al. Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals potential disease state and intervention specific biomarkers. PLoS ONE. 2014;9(11):e112835.","journal-title":"PLoS ONE"},{"key":"846_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2017.04.003","volume":"241","author":"SC Chien","year":"2017","unstructured":"Chien SC, Chen CY, Leu HB, Su CH, Yin WH, Tseng WK, Wu YW, Lin TH, Chang KC, Wang JH, et al. Association of low serum albumin concentration and adverse cardiovascular events in stable coronary heart disease. Int J Cardiol. 2017;241:1\u20135.","journal-title":"Int J Cardiol"},{"issue":"10","key":"846_CR38","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/aje\/kwj312","volume":"164","author":"BW Schalk","year":"2006","unstructured":"Schalk BW, Visser M, Bremmer MA, Penninx BW, Bouter LM, Deeg DJ. Change of serum albumin and risk of cardiovascular disease and all-cause mortality: longitudinal aging study Amsterdam. Am J Epidemiol. 2006;164(10):969\u201377.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"846_CR39","first-page":"290","volume":"85","author":"RF Gillum","year":"1993","unstructured":"Gillum RF. The association between serum albumin and HDL and total cholesterol. J Natl Med Assoc. 1993;85(4):290\u20132.","journal-title":"J Natl Med Assoc"},{"issue":"12","key":"846_CR40","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.bbalip.2012.08.011","volume":"1821","author":"LS Okuda","year":"2012","unstructured":"Okuda LS, Castilho G, Rocco DD, Nakandakare ER, Catanozi S, Passarelli M. Advanced glycated albumin impairs HDL anti-inflammatory activity and primes macrophages for inflammatory response that reduces reverse cholesterol transport. Biochim Biophys Acta. 2012;1821(12):1485\u201392.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"846_CR41","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1172\/JCI26206","volume":"117","author":"T Vaisar","year":"2007","unstructured":"Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117(3):746\u201356.","journal-title":"J Clin Invest"},{"issue":"8","key":"846_CR42","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1194\/jlr.M027367","volume":"53","author":"M Holzer","year":"2012","unstructured":"Holzer M, Wolf P, Curcic S, Birner-Gruenberger R, Weger W, Inzinger M, El-Gamal D, Wadsack C, Heinemann A, Marsche G. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res. 2012;53(8):1618\u201324.","journal-title":"J Lipid Res"},{"issue":"3","key":"846_CR43","first-page":"405","volume":"1821","author":"K Alwaili","year":"2012","unstructured":"Alwaili K, Bailey D, Awan Z, Bailey SD, Ruel I, Hafiane A, Krimbou L, Laboissiere S, Genest J. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochem Biophys Acta. 2012;1821(3):405\u201315.","journal-title":"Biochem Biophys Acta"},{"key":"846_CR44","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.atherosclerosis.2018.09.032","volume":"278","author":"SM Gordon","year":"2018","unstructured":"Gordon SM, Chung JH, Playford MP, Dey AK, Sviridov D, Seifuddin F, Chen YC, Pirooznia M, Chen MY, Mehta NN, et al. High density lipoprotein proteome is associated with cardiovascular risk factors and atherosclerosis burden as evaluated by coronary CT angiography. Atherosclerosis. 2018;278:278\u201385.","journal-title":"Atherosclerosis"},{"issue":"2","key":"846_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF00402539","volume":"35","author":"J Hilsted","year":"1992","unstructured":"Hilsted J, Christensen NJ. Dual effect of insulin on plasma volume and transcapillary albumin transport. Diabetologia. 1992;35(2):99\u2013103.","journal-title":"Diabetologia"},{"issue":"6","key":"846_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/BF00261700","volume":"18","author":"CE Mogensen","year":"1980","unstructured":"Mogensen CE, Christensen NJ, Gundersen HJ. The acute effect of insulin on heart rate, blood pressure, plasma noradrenaline and urinary albumin excretion. The role of changes in blood glucose. Diabetologia. 1980;18(6):453\u20137.","journal-title":"Diabetologia"},{"issue":"1","key":"846_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","volume":"13","author":"RS Rosenson","year":"2016","unstructured":"Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48\u201360.","journal-title":"Nat Rev Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0846-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-019-0846-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0846-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T06:47:52Z","timestamp":1721112472000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0846-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["846"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0846-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"16 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"43"}}